Suppr超能文献

开发一种抗 HER2 单链可变抗体片段构建体,用于在 中进行高产可溶性表达和一步色谱纯化。

Development of an Anti-HER2 Single-Chain Variable Antibody Fragment Construct for High-Yield Soluble Expression in and One-Step Chromatographic Purification.

机构信息

Department of Biotechnology, Research Institute (RIBHS), College of Biomedical and Health Science, Konkuk University, Chungju 27478, Republic of Korea.

Konkukbio Inc., Konkuk University, Chungju 27478, Republic of Korea.

出版信息

Biomolecules. 2023 Oct 11;13(10):1508. doi: 10.3390/biom13101508.

Abstract

Although single-chain variable fragment (scFv) is recognized as a highly versatile scaffold of recombinant antibody fragment molecules, its overexpression in often leads to the formation of inclusion bodies. To address this issue, we devised and tested four different constructs, named v21, v22, v23 and v24, for producing anti-human epidermal growth factor receptor 2 (HER2) scFv. Among them, the v24 construct obtained from N-terminal fusion of maltose-binding protein (MBP) and subsequent tobacco etch virus protease (TEV) was identified as the most efficient construct for the production of anti-HER2 scFv. Aided by an MBP tag, high-yield soluble expression was ensured and soluble scFv was liberated in cells via autonomous proteolytic cleavage by endogenously expressed TEV. The isolated scFv containing a C-terminal hexahistidine tag was purified through a one-step purification via nickel-affinity chromatography. The purified scFv exhibited a strong (nanomolar ) affinity to HER2 both in vitro and in cells. Structural and functional stabilities of the scFv during storage for more than one month were also assured. Given the great utility of anti-HER2 scFv as a basic platform for developing therapeutic and diagnostic agents for cancers, the v24 construct and methods presented in this study are expected to provide a better manufacturing system for producing anti-HER2 scFv with various industrial applications.

摘要

尽管单链可变片段 (scFv) 被认为是重组抗体片段分子的高度通用支架,但它在 中的过度表达往往会导致包涵体的形成。为了解决这个问题,我们设计并测试了四种不同的构建体,分别命名为 v21、v22、v23 和 v24,用于生产抗人表皮生长因子受体 2 (HER2) scFv。其中,通过麦芽糖结合蛋白 (MBP) 的 N 端融合获得的 v24 构建体,并随后进行烟草蚀纹病毒蛋白酶 (TEV) 的切割,被鉴定为生产抗 HER2 scFv 的最有效构建体。借助 MBP 标签,确保了高产可溶性表达,并通过内源性表达的 TEV 进行自主蛋白水解切割,使可溶性 scFv 在细胞中释放。含有 C 端六组氨酸标签的分离 scFv 通过镍亲和层析的一步纯化进行纯化。该纯化的 scFv 在体外和细胞中均表现出对 HER2 的强亲和力(纳摩尔级)。在储存超过一个月的时间内,scFv 的结构和功能稳定性也得到了保证。鉴于抗 HER2 scFv 作为开发癌症治疗和诊断剂的基本平台的巨大用途,本研究中提出的 v24 构建体和方法有望为生产具有各种工业应用的抗 HER2 scFv 提供更好的制造系统。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/210e/10605039/92c40b95eafc/biomolecules-13-01508-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验